Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amneal wins FDA approval for three generic drugs
Demeclocycline HCl tablets USP, in strengths of 150mg and 300mg, is an AB-Rated, therapeutically equivalent alternative to Declomycin (a trademark of Stonebridge Pharma) and is indicated in the
Demeclocycline HCl tablets USP, in strengths of 150mg and 300mg, is an AB-Rated, therapeutically equivalent alternative to Declomycin (a trademark of Stonebridge Pharma) and is indicated in the
This analysis was conducted using data from an open-label, flexible dose, 12-month extension study in which 326 children received Daytrana. The primary objective of this study was to
The drug candidate is a novel oral compound intended for the treatment of a common psychiatric disorder. Under an amended agreement with Taisho, which was initially executed in
Under the terms of the agreement, VWR will continue to sell and promote Pall’s filtration technologies to VWR customers in the US, Canada, Puerto Rico and throughout Europe.
This patent extends through the year 2022. Tobramycin inhalation powder (TIP) is being co-developed by Nektar and Novartis and is currently in Phase III development for the prevention
Under the terms of the license agreement with Bayer, ACT has acquired an anti-angiogenic receptor tyrosine kinase inhibitor entering Phase II clinical studies for colorectal cancer, amongst other
A double-blind, parallel-group, placebo-controlled Phase III study to evaluate the safety and efficacy of Lexapro, was conducted in multiple centers across the US. The primary endpoint was change
As part of the agreement, ImClone will utilize Champions Biotechnology’s Biomerk Tumorgrafts in the initial preclinical evaluation. Doug Burkett, president of Champions Biotechnology, said: “Studies suggest that our
Aquashunt is an implantable physiologic device that is designed to address the shortcomings of current glaucoma treatments. It is intended to reduce intraocular pressure physiologically by allowing excess
Menarini is seeking approval of Factive for the treatment of community-acquired pneumonia, acute bacterial exacerbations of chronic bronchitis and acute bacterial sinusitis. The regulatory review time in Europe